science

Mirvetuximab soravtansine

Mirvetuximab soravtansine is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Mirvetuximab soravtansine rather than just read about it. In short: Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.

Key takeaways

Mirvetuximab soravtansine belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Mirvetuximab soravtansine to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Mirvetuximab soravtansine from memory before moving on to harder problems.

Reference excerpt

Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. The most common adverse reactions, including laboratory abnormalities, were vision impairment, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin. Mirvetuximab soravtansine was approved for medical use in the United States in November 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Recipients are selected for therapy based on an FDA-approved test.

Adverse effects The product labeling includes a boxed warning for ocular toxicity.

History Efficacy was evaluated in study 0417 (NCT04296890), a single-arm trial of 106 participants with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants were permitted to receive up to three prior lines of systemic therapy. All participants were required to have received bevacizumab. The trial enrolled participants whose tumors were positive for FRα expression as determined by the above assay. Participants were excluded if they had corneal disorders, ocular conditions requiring ongoing treatment, Grade >1 peripheral neuropathy, or noninfectious interstitial lung disease. Efficacy was evaluated in study 0416 (MIRASOL, NCT04209855), a multicenter, open-label, active-controlled, randomized, two-arm trial in 453 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants were permitted to receive up to three prior lines of systemic therapy. The trial enrolled participants whose tumors were positive for FRα expression as determined by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Participants were randomized (1:1) to receive mirvetuximab soravtansine-gynx 6 mg/kg (based on adjusted ideal body weight) as an intravenous infusion every 3 weeks or investigator's choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) until disease progression or unacceptable toxicity. The results from this trial satisfy the post-marketing requirement of the previous accelerated approval for mirvetuximab soravtansine-gynx.

Society and culture

Legal status In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elahere, intended for the treatment of adults with folate receptor-alpha (FRα) positive epithelial ovarian, fallopian tube and primary peritoneal cancer. The applicant for this medicinal product is AbbVie Deutschland GmbH & Co. KG. Mirvetuximab soravtansine was authorized for use in the European Union in November 2024.

Names Mirvetuximab soravtansine is the international nonproprietary name (INN).

References

Further reading Gonzalez-Ochoa E, Veneziani AC, Oza AM (2023). "Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer". Clinical Medicine Insights: Oncology. 17 11795549231187264. doi:10.1177/11795549231187264. PMC 10387675. PMID 37528890. Porter RL, Matulonis UA (2023). "Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer". Expert Review of Anticancer Therapy. 23 (8): 783–796. doi:10.1080/14737140.2023.2236793. PMID 37458180. S2CID 259947077.

External links Clinical trial number NCT04296890 for "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA)" at ClinicalTrials.gov Clinical trial number NCT04209855 for "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Mirvetuximab soravtansine

Start with the simplest possible case. Write down what Mirvetuximab soravtansine claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Mirvetuximab soravtansine before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Mirvetuximab soravtansine ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Mirvetuximab soravtansine

In research: Mirvetuximab soravtansine appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Mirvetuximab soravtansine in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Mirvetuximab soravtansine is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antibody–drug conjugate, Drugs developed by AbbVie, Monoclonal antibodies for tumors, so understanding it makes those chapters shorter.
In everyday life: Look for Mirvetuximab soravtansine outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Mirvetuximab soravtansine” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Mirvetuximab soravtansine in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Mirvetuximab soravtansine means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Mirvetuximab soravtansine out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Mirvetuximab soravtansine in simple terms?

Why does Mirvetuximab soravtansine matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Mirvetuximab soravtansine?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Mirvetuximab soravtansine.